Cell Line-Derived Xenograft Models

Features and Purpose: Working with Crown Bioscience gives you access to our unique online database of well-characterized cell lines and CDX models, which includes standard of care and RNA-seq data to enable simple and rapid model selection. Our collection hosts over 200 validated and well-characterized CDX models covering subcutaneous, orthotopic, and systemic models. The collection includes 25 cancer types, including metastasis models (spontaneous and experimental) covering major cancer types such as: Breast, colon, liver, lung, melanoma, ovarian, pancreatic and prostate.

Features or Benefits:

• Access to XenoBase^®: a searchable database with CDX models, RNA-seq data, and standard-of-care references.
• PrimeXeno™ models: derived from PDX models, harboring novel therapeutic target mutations (ALK, FGFR2, FLT3, RSPO3).
• Validated CDX collection: 200+ models across 25 cancer types including metastasis, orthotopic, and systemic models.
• Bioluminescent imaging models: subcutaneous, orthotopic, and metastatic options.
• Ultrasound imaging models: 2D/3D high-frequency imaging without bioluminescent tagging.
• Engineered in vivo models: e.g., BaF3-EML4-ALK-WT/L1196M, BaF3-BCR-ABL-T315I.
• CRISPR capabilities: create stable knockouts/knock-ins to study resistance mechanisms.
• Downstream capabilities: including RNA-Seq, WES, PK/PD, and target validation.

Applications:

• Preclinical drug efficacy testing: including first-generation EGFR-TKI-resistant models (e.g., HCC827-ER1, HCC827-GR1).
• Mechanism of action studies: via multiple in vivo assay systems.
• In vivo imaging: using bioluminescent and ultrasound models for disease tracking.
• Resistance modeling: e.g., drug-resistant cell lines for KRASG12C inhibitor studies.
• Custom xenograft generation: from client-derived mutated or novel cell lines.
• Selectivity testing: with dual xenograft models.
• CRISPR-engineered models: to replicate clinical resistance scenarios.